



# **Les biomarqueurs sériques de l'inflammation en 2017: dans la pratique ?**

Dr Eric Dayer, PD  
Institut Central des Hôpitaux  
Hôpital du Valais, Sion

Berne, le 22 août 2017


# From rubor, calor dolor to (VIERGE AU CHANOINE, J. VAN EYCK, 1435) GIGANTOCELLULAR ARTERITIS - GCA



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



# Large scope of inflammation

## Exemples of what is to me significant



- 1. Systemic Inflammatory Response, fevers and Acute phase response**
- 2. CRP versus ESR: non-sense debate?**
- 3. Use combined with clinical score**
  1. Examples: Gigantocellular Arteritis (GCA, Horton) and rheumatoid arthritis
- 4. Procalcitonin (PCT) and bacteremia in emergency and intensive care units:**
  1. What is missing for personalized targeted therapy?
- 5. Auto-inflammatory diseases and Inflammasomes:**
  1. More frequent than expected by the rare genetic diseases, Gout,
  2. Consequences: AA amyloidosis, but therapeutic options
- 6. Unregulated cytokine storm:**
  1. Ferritin and macrophage activation syndrome (MAS)
- 7. Low-grade inflammation (hsCR) and CV risk**
- 8. Time to redefine inflammation:**
  - As innate immune response to insults to reestablish homeostasis

# SIRS (Systemic Inflammatory Response Syndrome)



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

- **The systemic response to a wide range of stresses.**
  - Temperature  $>38^{\circ}\text{C}$
  - Heart rate  $>90$  beats/min.
  - Respiratory rate  $>20$  breaths/min or  $\text{PaCO}_2 < 32$  mmHg.
  - White blood cells  $> 12,000$  cells/ml or  $< 4,000$  cells/ml or  $>10\%$  immature (band) forms.
- **Note**
  - Two or more of the following must be present.
  - These changes should be represent acute alterations from baseline in the absence of other known cause for the abnormalities.

*American College of Chest Physicians/Society of Critical Care Medicine Consensus.*

*Crit Care Med. 1992;20:864-874.*

## Disease groups causing recurrent fevers

---

- **The big three**

- Inflammatory, infectious:
  - persistent,
  - undertreated,
  - increased susceptibility
- Inflammatory, non-infectious
  - Autoimmune
  - Autoinflammatory
- Mostly inflammatory
  - Malignancies

- **The little three**

- Mostly non inflammatory:
  - Munchausen,
  - Drug fever,
  - Benign hyperthermia


- **Miscellaneous**

- Various mechanisms
  - Central fever
  - Dehydration...

*Kallinich T., Allergy 2013, EAACI Position paper*



# Systemic inflammatory response



# Pathophysiological changes in systemic inflammatory response

---



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

## Neuroendocrine changes

- Fever, somnolence, fatigue and anorexia

- Increased adrenal secretion of cortisol, adrenaline and glucagon

## Haematopoietic changes

- Anaemia

- Leucocytosis

- Thrombocytosis

## Metabolic changes

- Loss of muscle and negative nitrogen balance

- Increased Lipolysis

- Trace metal sequestration

- Diuresis

## Hepatic changes


- Increased blood flow

- Increased acute phase protein production

*Gabay and Kushner, NEJM, 1999*


---

## Acute phase response from hepatocytes





# Complex interplay of cells and stimuli



## CRP versus ESR: non-sense debate?

---

- **ESR: global evaluation with many pitfalls**
  - Used for its negative predictive value (*no inflammatory syndrome*)
  - Depend of viscosity, cells ,Ig and fibrinogen mostly
  - Most often concordant with CRP as screening
  - ESR >100 mm/Hour : infection 40%, endocarditis...
    - Malignant and renal 30%
    - Inflammatory systemic dis. 20%, Thyroid and Horton...
- **CRP: convenient, reactive acute phase protein marker**
  - Mostly produced by hepatocytes in response to IL-6
  - Highest increase in infections,
  - Very dynamic changes >1000 folds increase
  - Monitoring of the inflammatory state (resolution or treatment response)
  - hsCRP: useful to assess baseline CRP; associated with increased vascular risk
  - Low grade inflammation: 3-10 mg/L usually without clinical symptoms

## Increased ESR

## ESR

## Decreased ESR

Acute Heavy Metal Poisoning

Collagen Vascular Disease

Carcinomas

Cell or tissue injury

Gout arthritis

Infections

Inflammatory disorders

Leukemia

Myocardial infarction

Nephritis

Syphilis

Congestive heart failure

Polycythemia

Sickle Cell Anemia

Hôpital du Valais  
Spital WallisInstitut Central des Hôpitaux  
Zentralinstitut der Spitäler

## Factors causing false increases

Increased fibrinogen, globulin, cholesterol levels

High room temperature

Macrocytic anemia

Menstruation

Pregnancy

Tilting or lying down of the ESR tube

Drugs: Dextrane, methyldopa, methysergide, penicillamine, procainamide, theophylline, trifluoperidole, vitamin A

## Factors causing false decreases

Cachexia

Coagulation of the blood sample

Increase in bile salts

Increase in phospholipids

Making the sedimentation sample wait more than two hours

Increase in adrenal steroids

Hypofibrinogenemia

Hyperglycemia

Hyperalbuminemia

Leukocytosis

Microcytic anemia

Drugs: ACTH, cortisone, ethambutol, quinine, salicylates

(Adapted from A Textbook of Natural Medicine, Pizzorno and Murray, 1992)


# Acute phase proteins and the systemic inflammatory response



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



## 4 general stimuli:

1. Injury, trauma
2. Infection (Procalcitonin)
3. Inflammatory diseases (autoimmunity and autoinflammatory)
4. Many cancer


# C-reactive protein in patients undergoing curative surgery for colorectal cancer



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



# Assays of inflammatory markers and clinical use

Marker	Stability	Assay availability	Standard available	Interassay variability	Cost
ESR	Unstable	everywhere	yes	10%-15%	low
hsCRP	Stable	everywhere	yes	<10%	low
Procalcitonin	Stable	everywhere	yes	<15%	high
Fibrinogen	Stable	everywhere	yes	<10%	low
Ferritin	Stable	everywhere	yes	<10%	medium
Serum amyloid A	Stable	few	yes	<10%	medium
Cytokines (IL-6, IL1RA, TNF)	Unstable unless frozen	few	yes	<20%	high

*Dayer, Nature clinical rheumatology practice, 2007*



# Investigation of inflammatory syndrome


## A daily clinical question for physician



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



### ***Indication***

- Female 65 y, Febrile with inflammatory syndrom, **CRP:122 mg/L** without clear clinical localisation.
- Nuccal headache irradiating in the temporal regions of the head
- Left carotid artery examination normal. Painful cervical spine mobilisation
- Differential diagnosis : **GCA (Horton), spondylodiscitis ?**

### ***Investigations***

- Carotid and Temporal Doppler was normal, **NO halo sign**
- Unilateral temporal **biopsy was negative**

### ***CT scan conclusion***

- No carotid dissection found.
- **Circonférential peri-aortic hypodensity** of the aorta ascending, as well as thoracic, abdominal aorta, suggestive of large vessel vasculitis

K.E. (12.07.1952, F, 2307406)  
PET-CT au 18F-FDG du 28.07.2016





Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

## PET computerized tomography was performed





- **CRITERIA ACR: Giganto-cellular Arteritis (GCA) Horton**
  1. Beginning of symptoms  $\geq 50$  years
  2. New headache
  3. Temporal arteritis anomaly (pain or no pulse)
  4. High ESR( $\geq 50$  mm/H) or CRP  $> 50$  mg/L
  5. Temporal artery inflammation at the biopsy
    - monocellular inflammation or
    - granulomatous inflammation, often with multinucleate giant cells
- **If  $>3$  criteria = Sensitivity 93,5% and specificity 91,2%,**

# **Giganto-cellular arteritis:**

## **« classical » Horton $\pm$ large vessel vasculitis**

---



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

**If typical symptoms** : headache, temporal artery modifications, TA biopsy +

-> classical diagnosis (ACR)

**BUT isolated aortic or large vessel inflammation are often expressed only by inflammatory markers and no classical signs (> 50% of GCA have aortic involvement)**

-> Need of radiologic evaluation (PET-CT / angiIRM)

# Biomarkers in the management of Giant-Cell Arteritis and Polymyalgia Rheumatica.



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

## A Giant-Cell Arteritis

### Induction Therapy

Prednisone, 1 mg/kg/day  
Goal: resolution of laboratory and clinical abnormalities  
Course: generally 2–4 wk  
Begin bone-protective therapy  
Consider aspirin  
Consider gastroduodenal protection

### Maintenance Therapy

Taper prednisone by 10–20%/mo  
Monitor clinically  
Monitor acute-phase reactants (ESR and CRP)  
When dose <10 mg/day, taper by 1 mg/mo

### Management of Flares

Severe flare: repeat prednisone induction therapy  
Mild flare: increase prednisone by 10–20%  
Be cautious in treating elevated ESR or CRP level in absence of clinical symptoms  
Glucocorticoid-sparing agents: methotrexate, marginal benefit; infliximab, no benefit; dapsone, adalimumab, leflunomide, hydroxychloroquine, tocilizumab, azathioprine, anecdotal use

## B Polymyalgia Rheumatica

### Induction Therapy

Prednisone, 15–20 mg/day  
Goal: remission of myalgias, stiffness, constitutional symptoms  
Course: generally 1–2 mo  
Consider bone-protective therapy

### Maintenance Therapy

Taper prednisone by 20%/mo  
Monitor clinically  
Monitor acute-phase reactants (ESR and CRP)  
When dose reaches 10 mg/day, taper slowly

### Management of Flares

Reassess diagnosis, rule out vasculitis, consider temporal-artery biopsy, and consider large-vessel imaging  
Increase prednisone by 10–20%  
Reattempt taper  
Glucocorticoid-sparing agents: methotrexate marginally effective



# Disease activity score in rheumatoid arthritis



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

Enter Patient ID (for printing):

## Joint Scores

Tender:

Swollen:

To enter joint scores, I prefer to:

☒ Use Mannequin

☐ Type totals

Tender Joints



Swollen Joints



Figure 1

## Additional Measures

☒ ESR:  mm/hr

☐ CRP:  mg/l

☒ Patient Global Health:  mm


0 - Best Worst - 100

DAS28

Calculate

FORMULA: DAS28(4)

Decimal places in the CRP or ESR result are



DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. Cut-offs for remission and LDA are from Fleischmann *et al.*<sup>13</sup> DAS28-CRP, Disease Activity Score in 28 joints calculated with C reactive protein; DAS28-ESR, Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate; HDA, high disease activity; LDA, low disease activity.

3 levels

HDA: high disease activity

LDA: low disease activity

Remission

Essential  
to define  
treat to target

CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable.

Fleischmann RMD Open 2017

# Acute phase proteins during infection

## Changes in circulating concentrations of acute phase proteins during infections.

Viral and Bacterial Infections	
CRP	Stimulated by both viral and bacterial infections, but reaches higher values during bacterial infections <a href="#">[44, 77, 78]</a>
SAA	
Procalcitonin	
Ferritin	Elevated in viral infections <a href="#">[47, 56]</a>
Retinol	Decreased during infections <a href="#">[79]</a>
Haptoglobin	Not significantly different between neonates with and without an infection <a href="#">[80]</a>
$\alpha$ 1-antitrypsin	
LPS binding protein	Elevated in bacterial infections as compared to viral infections <a href="#">[68]</a>
sTREM-1	
Neutrophil lipocalin	More elevated in bacterial infections as compared to viral infections <a href="#">[81]</a>

CRP: C-reactive protein; SAA: serum amyloid A; sTREM-1: soluble triggering receptor expressed on myeloid cells-1.

**Table 1. Diagnostic Criteria for Sepsis, Severe Sepsis, and Septic Shock.\***

**Sepsis (documented or suspected infection plus  $\geq 1$  of the following)†**

**General variables**

- Fever (core temperature,  $>38.3^{\circ}\text{C}$ )
- Hypothermia (core temperature,  $<36^{\circ}\text{C}$ )
- Elevated heart rate ( $>90$  beats per min or  $>2$  SD above the upper limit of the normal range for age)
- Tachypnea
- Altered mental status
- Substantial edema or positive fluid balance ( $>20$  ml/kg of body weight over a 24-hr period)
- Hyperglycemia (plasma glucose,  $>120$  mg/dl [6.7 mmol/liter]) in the absence of diabetes

**Inflammatory variables**

- Leukocytosis (white-cell count,  $>12,000/\text{mm}^3$ )
- Leukopenia (white-cell count,  $<4000/\text{mm}^3$ )
- Normal white-cell count with  $>10\%$  immature forms
- Elevated plasma C-reactive protein ( $>2$  SD above the upper limit of the normal range)
- Elevated plasma procalcitonin ( $>2$  SD above the upper limit of the normal range)

**Hemodynamic variables**

- Arterial hypotension (systolic pressure,  $<90$  mm Hg; mean arterial pressure,  $<70$  mm Hg; or decrease in systolic pressure of  $>40$  mm Hg in adults or to  $>2$  SD below the lower limit of the normal range for age)
- Elevated mixed venous oxygen saturation ( $>70\%$ )‡
- Elevated cardiac index ( $>3.5$  liters/min/square meter of body-surface area)§

**Tissue-perfusion variables**

- Hyperlactatemia (lactate,  $>1$  mmol/liter)
- Decreased capillary refill or mottling

**Severe sepsis (sepsis plus organ dysfunction)**

**Septic shock (sepsis plus either hypotension [refractory to intravenous fluids] or hyperlactatemia)¶**

# Procalcitonin and bacterial infection

- Normally produced by parafollicular cells in thyroid
- 100-1000 fold increase in response to endotoxin, produced by most cells.
- Appropriate to improve the diagnosis and followup of bacterial infections in specific settings
- Included in the evaluation of septic shock, **predicts mortality** in emergency and intensive care units
- **Inappropriate to exclude bacterial infection in general practice**
- Appropriate to **exclude bacterial infection** in emergency settings
- Appropriate to **limit antibiotic use** and follow resolution of infection in ICU
- **Price issue to be solved** (excessive usage in ICU has to be limited) : high laboratory reagent costs)


# Procalcitonin and bacterial infection

- To rule out the presence of bacteraemia

- **SUBGROUPS**

- Sensitivity ranging
  - from 66% in immunocompromised/neutropenic patients
  - to 89% in ICU patients
- Specificities ranging
  - from 55% in bacteraemia versus local infections
  - to 78% in immunocompromised/neutropenic patients

- Biomarker guided therapy?





+++

Meningitis<sup>1</sup>

++

Acute Bronchitis<sup>2</sup>  
 Exacerbation of COPD<sup>2</sup>  
 Infection in Pulmonary fibrosis<sup>2</sup>  
 Infection in Asthma<sup>2</sup>

Pneumonia<sup>1</sup>

Upper respiratory  
 tract infection<sup>1</sup>


Congestive heart failure<sup>2</sup>

Abdominal infection<sup>4</sup>  
 Pancreatitis<sup>2</sup>

Severe Sepsis/  
 Septic Shock<sup>1</sup>






Urinary tract infection<sup>2</sup>  
 Blood stream infection<sup>4</sup>

Post operative infection<sup>4</sup>postoperative abdominal infection<sup>3</sup>Neutropenia<sup>2</sup>Arthritis<sup>4</sup>Endocarditis<sup>3</sup>Appendicitis<sup>3</sup>

+







# Procalcitonin retesting interval and datamining in our institution





Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

## Evaluation of the cost of early retesting of PCT


1. 18.2% under 48H set as Minimal Retesting interval (MRI)
2. 80% Due to significant biological variation



Depending of this algorithm, reevaluation of non conformity is done and the % of non conformity pass from 18.2% to 11.9% :

Initial PCT [µg/L]	MRI	% below MRI
≤ 0.25	6 h	0.1
> 0.25	48 h	11.8

Effort must be done for after initiation of antibiotics treatment when PCT is recheck



It appeared that the transition of PCT from normal to pathological values, at the beginning of the infection, occurred much faster than the inverse transition, when PCT returned to normal values.

**USE different MRI in the ascending phase and in the recovery phase to lower the cost**

## Auto-inflammatory diseases and Inflammasomes:



1. **More frequent than expected by the genetic diseases,**
2. **Exemple: Familial Mediterranean Fever**
3. **Consequences: AA amyloidosis, but therapeutic option**
  - **Knowledge from genetic disease such as periodic fevers**
  - **Inflammation occurring without pathogens or trauma**
  - **Recurrent state with spontaneous resolution in variable duration**
  - **Exemple: FMF = Familial Mediterranean Fever**

### Major criteria

#### Typical attacks

1. Peritonitis (generalized)
2. Pleuritic (unilateral) or pericarditis
3. Monoarthritis (hip, knee, ankle)
4. Fever alone
5. Favorable response to colchicine

**typical acute attack =**

More than 3 febrile identical episodes

And central 38°C

Duration: between 12 H et 3 D

**And 1 criterium associated**

**FMF: Se 57% Sp 99%**

# Autoinflammation : pathology of the innate immunity



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

Autoinflammation		Autoimmunity
INNATE	Immune dysregulation	ADAPTATIVE
Monocytes, macrophages, neutrophils	Predominant cells	T and B cells
IL-1,TNF, IL-12(IL-17), IL18	Cytokines target used	IFN g,IL-4 (IL-17),IL-6
Neutrophil and macrophage organ damage	Pathogenesis of organ damage	Autoantibody, Ag specific T cells
IL-1 mediated autoinflammatory dis.	Diseases examples	Thyroiditis, RA, SLE, ALPS

## ***Pathogen? How are they recognized?***

Receptors :                      -called : pattern recognition receptors = PRR

Ligands :

-**PAMPS** : pathogen associated molecular patterns

- conserved structures, essential to microbes,
- absent in mammals


- **LPS, RNA ds, flagellin, oxydative stress,**

-**DAMPS** : danger associated molecular patterns  
ATP...




# Physiopathology of FMF: Inflammasome

FMF



AIM: absent in melanoma; BIRs: baculovirus IAP-repeat; CARD: caspase recruitment domain; CASP: caspase; LRRs: leucine-rich repeats; NACHT: nucleotide binding/oligomerization domain; NAIP: NLR family, apoptosis inhibitory protein; NLRP: nucleotide-binding domain, leucine-rich repeat-containing receptor protein; PYD: pyrin domain



**Fig. 2** The pyrin inflammasome. At steady state, the phosphorylation of pyrin on serine residues S208 and S242 by the kinases PKN1/2 results in the interaction of pyrin with 14-3-3 protein, a chaperone which sequesters pyrin and blocks its ability to form an inflammasome. Decreased geranylgeranyl pyrophosphate (secondary to deficiency in mevalonate kinase, MVK) or addition of toxins A or B from *Clostridium difficile* or YopE/T from *Yersinia pestis* inactivate the Rho GTPases, leading to

inactivation of the kinases PKN1/2. This inhibition results in the dephosphorylation of pyrin, its release from the 14-3-3 protein, the activation of the pyrin inflammasome and its interaction with microtubules, and the release of IL-1 $\beta$ . *MEFV* mutations associated with familial Mediterranean fever (*red star*) decrease the threshold of activation of the pyrin inflammasome. Colchicine inhibits the interaction of the pyrin inflammasome with the cytoskeleton

# Autoinflammatory diseases

## Monogenic autoinflammatory diseases

### Cryopyrinopathies

FCAS, MWS, NOMID

### IL-1 mediated bone diseases

DIRA, Majeed

### Classic hereditary fever syndromes

FMF, TRAPS, HIDS

\*PAPA

\*PGA

\*FCAS2

## Autoinflammatory diseases with unknown genetics

Schnitzler syndrome

SoJIA/AOSD

Behcet's disease

SAPHO/CRMO

PFAPA

## Metabolic diseases with proposed IL-1 mediated pathology

Gout/pseudogout

Type 1/Type 2 DM

CAD/stroke/heart remodeling

Metabolic syndrome

\*Partial response to IL-1 inhibition suggests involvement of additional cytokine pathways.

## Pro-inflammatory markers

IL-1 beta  
IL-6  
TNF- $\alpha$

## Anti-inflammatory markers

TGF- $\beta$   
IL-12  
Inducible IL-35









# Spontaneous recovery linked to autophagy..


Zhenyu Zhong, Atsushi Umemura, Elsa Sanchez-Lopez, ..., Maria T. Diaz-Meco, Jorge Moscat, Michael Karin

## Correspondence

karinoffice@ucsd.edu

## In Brief

NF- $\kappa$ B restrains its own inflammation-promoting activity in macrophages by promoting p62-mediated removal of mitochondria that have been damaged after macrophages encounter various NLRP3-inflammasome activators.




# Schematic drawing depicting SAA synthesis and interaction with its receptors.



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



Richard D. Ye, and Lei Sun J Leukoc Biol 2015;98:923-929

## SAA for auto-inflammatory diseases

---

- **Linked to inflammasome associated disease with persistent elevated levels**
- **Up to 40% of recurrent fevers develop secondary AA amyloïdosis**
- **Potent inducer of IL1 via TL2 and 4....**
- **But also an inducer of recovery mechanism like M2 macrophage, Il-10...**
- **Can be used as a marker of response to treatment**

## Serum Amyloid A (SAA)




Fig.2 Synthesis of SAA and catabolic pathway leading to amyloidogenesis.

## Predictors of mortality in AA amyloidosis

	P value	RR	95% CI
Age at dx	<0.001	1.53	1.34-1.74
Periodic fever syndroms	0.03	0.36	0.14-0.88
Median SAA (per doubling)	<0.001	1.27	1.16-1.40
Onset of ESRF	<0.001	2.97	2.10-4.21
Amyloid regression	0.04	0.13	0.02-0.94
Median survival under 13 years			

Lachmann HJ, NEJM 2007




# Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature

itaux  
iler

-1  
-2  
-3

T. Lane, J.D. Gillmore, A.D. Wechalekar, P.N. Hawkins, H.J. Lachmann

- Response to anti-IL-6 lead to suppression of the inflammatory stimulus
- Decrease of amyloid deposition



# Macrophage activation syndrome/ferritin

---

## *Classification of macrophage activation syndrome in systemic juvenile idiopathic arthritis*

A febrile patient with known or suspected systemic juvenile idiopathic arthritis is classified as having macrophage activation syndrome if the following criteria are met:

Ferritin >684 ng/ml

*and* any 2 of the following:

Platelet count  $\leq 181 \times 10^9$ /liter


Aspartate aminotransferase >48 units/liter

Triglycerides >156 mg/dl

Fibrinogen  $\leq 360$  mg/dl

# Macrophage activation syndrome

## Cytokines storm leading to extracellular ferritin release




# Follow up and treatment of a macrophage activation syndrome




Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler



# Chronic inflammation/High basal hsCRP





# hsCRP and cardiovascular risk

Etude	Design	Sexe	Risque relatif cardiovasculaire selon le taux de hsCRP (4 <sup>e</sup> vs 1 <sup>er</sup> quartiles)	AUC des facteurs de risque traditionnels seuls	AUC pour la hsCRP combinée aux facteurs de risque traditionnels
Woman's health study (Ridker et coll., 2002)	Prospective	Femmes	2,3	0,81	0,81
Rotterdam Study (van der Meer et coll., 2003)	Nested case-control	Hommes et femmes	1,2	0,746	0,748
MONICA Augsburg Study (König et coll., 2004)	Prospective	Hommes	2,2	0,735	0,75
Reykjavik Cohort Study (Danesh et coll., 2004)	Nested Case-Control	Hommes et femmes	1,4	0,64	0,65
Framingham Offspring Study (Rutter et coll., 2004)	Prospective	Hommes et femmes	1,9	0,74	0,74
Framingham Heart Study (Wilson et coll., 2005)	Prospective	Hommes et femmes	1,6	0,80	0,80
Cardiovascular Heart Study (Shlipak et coll., 2005)	Prospective	Hommes et femmes	Non disponible	0,73	0,72*

## Practical implications:

1. Classical risk factors predict more than 90% of futur myocardial infarcts
2. Patients with intermediate risk may benefit from hsCRP to start treatment
3. These biomarkers should not be used for population screening
4. Same for new biomarkers, so far as we know now



## Association Between Carotid Atherosclerosis and Markers of Inflammation in Rheumatoid Arthritis Patients and Healthy Subjects

Inmaculada del Rincón,<sup>1</sup> Ken Williams,<sup>1</sup> Michael P. Stern,<sup>1</sup> Gregory L. Freeman,<sup>1</sup>  
Daniel H. O’Leary,<sup>2</sup> and Agustín Escalante<sup>1</sup>

**Table 6.** Relationship between C-reactive protein (CRP) level and carotid artery plaque\*

CRP, mg/liter	No. of carotid vessels imaged	Carotid vessels with plaque, no. (%)†	Odds ratio	95% CI
0–1.0	77	8 (10)	1.0	Referent
1.1–2.3	89	28 (31)	6.61	1.79–24.39
2.4–4.8	118	33 (28)	5.59	1.52–20.54
4.9–30	279	89 (32)	6.75	1.94–23.41
>30	41	15 (37)	8.31	1.98–34.94

\* See Table 2 for other definitions.

† *P* for trend = 0.001 unadjusted, ≤0.001 age- and sex-adjusted, ≤0.001 age-, sex-, and cardiovascular risk factor-adjusted.

## Low grade « inflammation » : CRP 3-10 mg/L

Usually asymptomatic leading to latter consequences  
Leading to a new definition of inflammation:




Figure 3: The role of inflammasomes in metabolic syndrome. During obesity, the NLRP3 inflammasome is activated by obesity-associated DAMPs in multiple tissues and cell types; the resultant pro-inflammatory-induced state often leads to a deterioration in metabolic functions. In adipose tissue, palmitate and ceramides activate the NLRP3 inflammasome in infiltrating macrophages, which leads to an enhancement of insulin resistance. In addition,...

0 Recommendations

## Inflammasomes in health and disease

Nature 481(7381):278-86 · January 2012

# Redefining INFLAMMATION

## INNATE immune response to potentially harmful stimuli such as pathogens, injury and metabolic stress To restore optimal homeostatic state

TABLE 1. Comparison of acute, low-grade, and autoinflammatory inflammation

Parameter	Infection	Tissue injury	Low-grade inflammation	Autoinflammatory diseases
Cause	Pathogens	Trauma, tissue infarction	Metabolic malfunction	Usually spontaneous
Mediators	Molecules and cells of the innate immune response	Molecules and cells of the innate immune response	Molecules and cells of the innate immune response	Molecules and cells of the innate immune response
Classic signs of inflammation	+++	+++	None	+++
CRP response	+++	+++	+	+++
Purpose	Defense healing and repair	Healing and repair	Restoration of homeostasis	None apparent
Triggering mechanism	Pattern recognition molecules, notably for PAMPs and DAMPs	Pattern recognition molecules, notably for DAMPs	Sentinel cells that monitor for tissue stress, notably the UPR	Genetically based dysregulation

DAMP, damage-associated molecular patterns; PAMP, pathogen-associated molecular pattern. Plus symbols indicate magnitude.

1. **ESR as Inflammation biomarker to rule out inflammatory syndrome**
2. **Use of biomarkers in follow up alone or in clinical score of disease activity (GCA; DAS - RA)**
3. **PROCALCITONIN included in ICU septic shock evaluation and exclusion of bacteremia: not yet directing AB treatment**
4. **Chronic residual inflammation or recurrent fevers with long term consequence as AA amyloidosis: Treatment options: anti-IL6 (monitoring with SAA)**
5. **Macrophage activation syndrome: FERRITIN as an essential marker of macrophage**
6. **Basal hs CRP levels and risk evaluation: screening limited**
7. **Time to redefine inflammation**



Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

---

# Thank you for your attention

Any question ?





Hôpital du Valais  
Spital Wallis



Institut Central des Hôpitaux  
Zentralinstitut der Spitäler

---